Ecuador Raises Tariffs on Colombian Imports to 50% Amid Border Security Dispute 
USITC to Review Impact of Revoking China’s PNTR Status, Potentially Raising Tariffs on Chinese Imports 
OpenAI Pentagon AI Contract Adds Safeguards Amid Anthropic Dispute 
Anthropic Refuses Pentagon Request to Remove AI Safeguards Amid Defense Contract Dispute 
Australian Dollar Rallies on Hawkish RBA Outlook; Yen Slips as BOJ Faces Political Pressure 
BlueScope Steel Shares Drop After Rejecting Revised A$15 Billion Takeover Bid 
U.S. Stocks Close Lower as Hot PPI Data, Nvidia Slide Weigh on Wall Street 
PBOC Scraps FX Risk Reserves to Curb Rapid Yuan Appreciation 
Samsung and SK Hynix Shares Hit Record Highs as Nvidia Earnings Boost AI Chip Demand 
Netflix Declines to Raise Bid for Warner Bros. Discovery Amid Competing Paramount Skydance Offer 
Snowflake Forecasts Strong Fiscal 2027 Revenue Growth as Enterprise AI Demand Surges 
Oil Prices Steady as US-Iran Nuclear Talks and Rising Crude Inventories Shape Market Outlook 
U.S.-Canada Trade Talks Resume as Trump Administration Reviews USMCA 
Trump Media Weighs Truth Social Spin-Off Amid $6B Fusion Energy Pivot 
Gold Prices Rebound as U.S. Tariffs, Fed Policy and Iran Talks Drive Market Sentiment 
Pentagon Weighs Supply Chain Risk Designation for Anthropic Over Claude AI Use 
Trump Warns Iran as Gulf Conflict Disrupts Oil Markets and Global Trade 
GSK and Medicago are now closer to debuting the world's first plant-based COVID-19 vaccine after the completion of phase 3 clinical trial for the efficacy and safety of the immunization that they are developing.
This week, GlaxoSmithKline and Medicago announced getting positive results for their plant-based vaccine candidate for coronavirus. The product is Canadian-made, and it was found to be 71% effective after going through the third level of tests.
According to Canada's CTV News, Medicago Inc., the biotech company headquartered in Quebec, said their Phase 3 placebo-controlled study for their COVID-19 vaccine was conducted in over 24,000 subjects based in six countries.
The participants were 18 years old and older, and the outcome revealed the 71% effectiveness against all variants of coronavirus that were active at the time of the trial. The company further said that they did not find any serious safety issues as well.
The positive results were forwarded to regulators already so it can be authorized to release the world's very first plant-based COVID-19 vaccine worldwide. Just like the other available vaccines today, Medicago and GSK's candidate is also a two-dose injection.
Then again, while the biotech firm said its new vaccine was tested to be effective against the Delta variant but the trial did not include the Omicron variant because it was not yet circulating when the study began.
Currently, the vaccine producer is now processing documents and requirements for filing with health regulators in the U.K., U.S., and other nations. They will also forward the necessary data to World Health Organisation (WHO).
"This is an incredible moment for Medicago and for novel vaccine platforms. The results of our clinical trials show the power of plant-based vaccine manufacturing technology," Medicago chief executive officer and president Takashi Nagao said in a press release. "If approved, we will be contributing to the world's fight against the COVID-19 pandemic with the world's first plant-based vaccine for use in humans."
Finally, Nagao also expressed his gratitude to everyone who took part in the clinical trials, including its partners at GSK, Mitsubishi Tanabe Pharma Corporation, and the government of Canada and Quebec. He did not forget to thank Medicago's workers and shareholders, who are also committed to work on advancing vaccine science at a time when the world needs it.
